Literature DB >> 11403208

Species dependence for binding of small molecule agonist and antagonists to the C5a receptor on polymorphonuclear leukocytes.

T M Woodruff1, A J Strachan, S D Sanderson, P N Monk, A K Wong, D P Fairlie, S M Taylor.   

Abstract

This study investigated the receptor binding affinities of a C5a agonist and cyclic antagonists for polymorphonuclear leukocytes (PMNs) isolated from human, sheep, pig, dog, rabbit, guinea pig, rat and mouse. The affinities of the two small molecule antagonists, F-[OPdChaWR] and AcF-[OPdChaWR], and the agonist, YSFKPMPLaR, revealed large differences in C5a receptor (C5aR) affinities between species. The antagonists bound to human, rat and dog PMNs with similar high affinities, but with lower affinities to PMNs from all other species. The C5a agonist also bound with varying affinities between species, but showed a different affinity profile to the antagonists. In contrast, recombinant human C5a had similar affinity for PMNs of all species investigated. The low correlation between the affinities of the antagonists and the agonist between species either suggests that different receptor residues are important for distinguishing between agonist/antagonist binding, or that the agonist and antagonist peptides bind to two distinct sites within the C5aR.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11403208     DOI: 10.1023/a:1011036414353

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  31 in total

1.  Endotoxin-induced shock in the rat. A role for C5a.

Authors:  G Smedegård; L X Cui; T E Hugli
Journal:  Am J Pathol       Date:  1989-09       Impact factor: 4.307

2.  Cloning and characterization of the guinea pig C5a anaphylatoxin receptor: interspecies diversity among the C5a receptors.

Authors:  Y Fukuoka; J A Ember; A Yasui; T E Hugli
Journal:  Int Immunol       Date:  1998-03       Impact factor: 4.823

3.  Effects of a new C5a receptor antagonist on C5a- and endotoxin-induced neutropenia in the rat.

Authors:  A Short; A K Wong; A M Finch; G Haaima; I A Shiels; D P Fairlie; S M Taylor
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

4.  Expression of the receptor for complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system.

Authors:  P Gasque; S K Singhrao; J W Neal; O Götze; B P Morgan
Journal:  Am J Pathol       Date:  1997-01       Impact factor: 4.307

5.  Pharmacological characterization of antagonists of the C5a receptor.

Authors:  N J Paczkowski; A M Finch; J B Whitmore; A J Short; A K Wong; P N Monk; S A Cain; D P Fairlie; S M Taylor
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

6.  Two-site binding of C5a by its receptor: an alternative binding paradigm for G protein-coupled receptors.

Authors:  S J Siciliano; T E Rollins; J DeMartino; Z Konteatis; L Malkowitz; G Van Riper; S Bondy; H Rosen; M S Springer
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

7.  Structural diversity in the extracellular faces of peptidergic G-protein-coupled receptors. Molecular cloning of the mouse C5a anaphylatoxin receptor.

Authors:  C Gerard; L Bao; O Orozco; M Pearson; D Kunz; N P Gerard
Journal:  J Immunol       Date:  1992-10-15       Impact factor: 5.422

8.  Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates.

Authors:  J H Stevens; P O'Hanley; J M Shapiro; F G Mihm; P S Satoh; J A Collins; T A Raffin
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

9.  Site-directed mutagenesis of conserved charged residues in the helical region of the human C5a receptor. Arg2O6 determines high-affinity binding sites of C5a receptor.

Authors:  U Raffetseder; D Röper; L Mery; C Gietz; A Klos; J Grötzinger; A Wollmer; F Boulay; J Köhl; W Bautsch
Journal:  Eur J Biochem       Date:  1996-01-15

10.  Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease.

Authors:  Y Wang; S A Rollins; J A Madri; L A Matis
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-12       Impact factor: 11.205

View more
  14 in total

1.  PMX-53 as a dual CD88 antagonist and an agonist for Mas-related gene 2 (MrgX2) in human mast cells.

Authors:  Hariharan Subramanian; Sakeen W Kashem; Sarah J Collington; Hongchang Qu; John D Lambris; Hydar Ali
Journal:  Mol Pharmacol       Date:  2011-03-11       Impact factor: 4.436

2.  Complement receptor C3aR1 controls neutrophil mobilization following spinal cord injury through physiological antagonism of CXCR2.

Authors:  Faith H Brennan; Trisha Jogia; Ellen R Gillespie; Linda V Blomster; Xaria X Li; Bianca Nowlan; Gail M Williams; Esther Jacobson; Geoff W Osborne; Frederic A Meunier; Stephen M Taylor; Kate E Campbell; Kelli Pa MacDonald; Jean-Pierre Levesque; Trent M Woodruff; Marc J Ruitenberg
Journal:  JCI Insight       Date:  2019-05-02

Review 3.  Recent developments in low molecular weight complement inhibitors.

Authors:  Hongchang Qu; Daniel Ricklin; John D Lambris
Journal:  Mol Immunol       Date:  2009-10-02       Impact factor: 4.407

Review 4.  Complement-Mediated Events in Alzheimer's Disease: Mechanisms and Potential Therapeutic Targets.

Authors:  Andrea J Tenner
Journal:  J Immunol       Date:  2020-01-15       Impact factor: 5.422

Review 5.  Function, structure and therapeutic potential of complement C5a receptors.

Authors:  P N Monk; A-M Scola; P Madala; D P Fairlie
Journal:  Br J Pharmacol       Date:  2007-07-02       Impact factor: 8.739

6.  Insights into the mechanism of C5aR inhibition by PMX53 via implicit solvent molecular dynamics simulations and docking.

Authors:  Phanourios Tamamis; Chris A Kieslich; Gregory V Nikiforovich; Trent M Woodruff; Dimitrios Morikis; Georgios Archontis
Journal:  BMC Biophys       Date:  2014-08-12       Impact factor: 4.778

7.  The Receptor for Advanced Glycation Endproducts Does Not Contribute to Pathology in a Mouse Mesenteric Ischemia/Reperfusion-Induced Injury Model.

Authors:  Mike C L Wu; Timothy D Gilmour; Susanna Mantovani; Trent M Woodruff
Journal:  Front Immunol       Date:  2015-12-07       Impact factor: 7.561

8.  Developmental activities of the complement pathway in migrating neurons.

Authors:  Anna Gorelik; Tamar Sapir; Rebecca Haffner-Krausz; Tsviya Olender; Trent M Woodruff; Orly Reiner
Journal:  Nat Commun       Date:  2017-05-02       Impact factor: 14.919

9.  Increased Susceptibility of Humanized NSG Mice to Panton-Valentine Leukocidin and Staphylococcus aureus Skin Infection.

Authors:  Ching Wen Tseng; Juan Carlos Biancotti; Bethany L Berg; David Gate; Stacey L Kolar; Sabrina Müller; Maria D Rodriguez; Kavon Rezai-Zadeh; Xuemo Fan; David O Beenhouwer; Terrence Town; George Y Liu
Journal:  PLoS Pathog       Date:  2015-11-30       Impact factor: 6.823

10.  Serping1/C1 Inhibitor Affects Cortical Development in a Cell Autonomous and Non-cell Autonomous Manner.

Authors:  Anna Gorelik; Tamar Sapir; Trent M Woodruff; Orly Reiner
Journal:  Front Cell Neurosci       Date:  2017-06-16       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.